Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

February 18, 2025

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 61 min

Earnings Call Speaker Segments

Cecilia Furlong

executive
#1

Thanks, Operator, and I appreciate everyone being here today as we go over Penumbra's results for Q4 and the entire 2024 fiscal year. You can find the press release along with the financial tables — including a reconciliation from GAAP to non-GAAP — in the Investors section of our site, www.penumbrainc.com. Throughout this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering topics like our financial results, commercialization efforts, clinical trials, regulatory standing, quality, compliance, and business trends. Actual outcomes may differ materially from what those statements state or suggest, because of various risks and uncertainties — among them those described in our 10-K for the year ended December 31st, 2024, which we expect to file with the SEC on February 18, 2025. So we urge you not to place excessive reliance on these forward-looking statements, and we encourage you to look at our periodic SEC filings, including that 10-K, for a fuller discussion of these factors and other risks that could impact our future results or the market price of our stock. Penumbra undertakes no obligation to update or revise any forward-looking statements, whether due to new information, future events, developments, or anything else. On this call, the Q4 2024 and full year 2024 financial results are presented on a non-GAAP basis. Non-GAAP revenue, gross profit, gross margin, operating income, and operating margin all leave out a $5.8 million reserve tied to Italian payback legislation. Additionally, for full year 2024, non-GAAP operating expenses, operating income, and operating margin leave out expenses related to Immersive Healthcare impairment charges of $76.9 million, Immersive Healthcare business wind down expenses of $5 million, non-recurring litigation expenses of $4.8 million, and amortization of finite lived intangible assets of $4.8 million. The matching GAAP figures and the reconciliation between GAAP and non-GAAP financial measures appear in the press release we posted. Adjusted EBITDA for Q4 2024 and full year 2024, respectively, leaves out the Italian payback reserve, one-time Immersive Healthcare impairment charges, Immersive Healthcare wind down expenses, non-recurring litigation-related expenses, stock compensation expense, depreciation and amortization, provision for income taxes, and interest income expenses. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then go over our financial results for the fourth quarter and full year 2024, and Jason Mills, our Executive Vice President of Strategy, will cover our 2025 guidance. With that, I'll hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Cecilia. Good afternoon, everyone, and thanks for being with us on Penumbra's call covering both the fourth quarter and the full year 2024. Excluding the Italian payback adjustment, our fourth quarter revenue came to $321.3 million, which works out to underlying growth of 12.9% year over year on an adjusted basis and 13% on a constant currency basis. Growth was again paced by our U.S. thrombectomy business, where our comprehensive, proprietary CAVT portfolio turned in yet another dominant performance, building momentum as the quarter progressed and finishing the year strongly. U.S. thrombectomy sales for the fourth quarter rose 27.3% year over year, reaching $180.6 million, and our U.S. VTE franchise posted robust year-over-year revenue growth of 41%. The rest of our U.S. thrombectomy franchise also performed very well, matching what we had expected. That fourth quarter wrapped up a solid overall 2024, as full year revenue grew 13.4% year over year to more than $1.2 billion, while our U.S. Thrombectomy business delivered revenue of $646.7 million, up 26.8% versus 2023. Over the course of the year, we evolved and expanded our commercial team, sharpened and concentrated our focus on the interventional business by exiting Immersive Healthcare, and put money into producing high-quality clinical and health economic data to further bolster and showcase CAVT's value, all while keeping innovation as a priority. We brought nine new products to the U.S. commercial market, among them the new CAVT products Flash 2.0, Lightning Bolt 6F with TRX, and Lightning Bolt 12. Outside the U.S., we grew CAVT's footprint into Europe and additional OUS geographies and took steps to optimize our geographic presence in support of long-term growth and profitability. At the same time, 2024 also showcased the strong profitability profile of our business. Gross margin in the fourth quarter was 67.4%, expanding 170 basis points over the prior year period, while operating income came in at $48.6 million, or 15.1% of revenue, up 200 basis points over the prior year period. During the quarter, we generated $49.1 million in operating cash. Looking ahead, we remain on track to reach a gross margin profile over 70% by the end of 2026, consistent with the timeline we communicated previously, and we expect operating margin expansion to outpace gross margin expansion for the foreseeable future. In addition, we recently signed a contract to build a manufacturing facility in Costa Rica to expand our manufacturing capacity efficiently. As a result, we are well positioned, leveraging favorable product mix, operating efficiencies, and disciplined spend to keep increasing our profitability and operating cash flow going forward. Turning to our U.S. peripheral business, Lightning Flash 2.0 continued to lead overall growth in the fourth quarter thanks to its competitive benefits versus analog technologies, specifically the speed and safety with which Flash 2.0 removes blood clots in VTE patients, which is driving expanded physician interest and adoption, as well as broader and deeper account penetration. During the quarter, we also began the commercial rollout of Lightning Bolt 12, bringing our proprietary modulated aspiration technology to the venous anatomy and larger arteries, offering the latest generation CAVT solution for these vessel sizes. Early responses have been quite encouraging, and we're eager to keep broadening the deployment of this technology during 2025. On the whole, momentum and share gains kept building across our U.S. VTE franchise through Q4, and December stood out as the biggest month for VTE procedure volumes we've ever recorded; over in our U.S. arterial business, Lightning Bolt 7 turned in another robust showing, fueling an acceleration in sequential growth for our arterial franchise. Lightning Bolt 6F made its first contributions during the fourth quarter, and with Bolt 6F now commercially introduced, our arterial-focused CAVT portfolio reaches smaller vessels, among them arteries located below the knee. Although early responses to Bolt 6F and to our ever more comprehensive arterial CAVT portfolio have been favorable, and as we look toward 2025, we see a substantial opportunity for Bolt 7 paired with Bolt 6F to speed up conversion of physicians away from open surgery or lytics toward CAVT. Much like our venous business, this December we treated a larger number of U.S. patients with arterial clot than in any month before. Our CAVT technology's proprietary mechanism reliably clears blood clots more quickly and more safely than analog technology. That being said, we remain at an early stage in reaching and treating the more than 800,000 U.S. patients each year who have VTE and arterial clot, plus the still larger patient population abroad carrying venous and arterial clot burden. To widen CAVT's reach and its capacity to treat more patients, we launched what we call our Market Access Initiatives. These efforts aim to boost awareness both of CAVT's clinical benefits and of the economic value it brings to hospital systems. This past November, in a late-breaking session at the VIVA Conference in Las Vegas, Dr. Parag Patel offered the first public look at certain results from our Market Access Initiatives. The retrospective outcomes analysis Dr. Patel presented examined intermediate-risk PE patients treated either with CAVT or with anticoagulation, catheter-directed lytics, or other mechanical thrombectomy approaches. According to the data, treatment with CAVT, relative to other treatment modalities, produced a decrease in composite complications along with a meaningful economic improvement for hospitals. We plan to keep refreshing our analysis so it captures the advantages of our newest generation CAVT technologies, and we look forward to showcasing Flash 2.0's outcomes down the road. Looking forward, we're set to share further data sets centered on CAVT's use in DVT and arterial patients at a major medical conference within the coming months. Turning to our neurovascular business, our U.S. stroke thrombectomy business delivered strong results yet again, with revenue growth speeding up compared with the third quarter. Across the full year, our market-leading FDA-cleared aspiration portfolio — headed by RED 72 featuring our proprietary SENDit technology and RED 43, together with RED 62, RED 68, and RED 72 — expanded by nearly 20% against 2023, comfortably outpacing growth in the underlying U.S. stroke market. As we head into 2025, we're the clear leader in the market, and going forward, we're getting ready to introduce Thunderbolt, our proprietary CAVT technology, into the neurovascular space. Patient follow-up in our Thunder trial wrapped up as anticipated in late December, and we'll share further updates down the road when it makes sense. We've witnessed the advantages our proprietary bolt technology brings to individuals suffering from peripheral vascular clot — in particular, how quickly it can remove a variety of clot morphologies through a procedure that is both safe and straightforward. It's thrilling to extend this technology into the neurovascular arena, opening a new chapter in stroke care and further strengthening our market-leading standing in stroke thrombectomy; we're entering 2025 with considerable momentum behind our CAVT technology portfolio. Through CAVT, we're fueling a transition from analog to digital. We're setting up our organization to concentrate intensely on the substantial thrombectomy opportunity that lies ahead for CAVT, while simultaneously bolstering our leadership position in embolization as well as access via further innovation and commercial emphasis. As we proved in 2024, we'll keep pushing gross margin expansion and operating efficiencies and deliver growing profitability while investing aggressively in innovation, clinical and health economic data, and our commercial team to broaden and reinforce our position as the world's leading thrombectomy company. I'll now hand the call over to Maggie to walk through our financial results for the fourth quarter and full year 2024.

Maggie Yuen

executive
#3

Thanks, Adam. Good afternoon, everybody. On today's call, I'll go over our financial performance for Q4 and the entire 2024 fiscal year. The figures we're discussing are non-GAAP, meaning they leave out the adjustment Cecilia mentioned — that includes the $5.8 million reserve tied to Italian government legislation that forces medical device companies to help cover any shortfall from Italian budget overspending on medical devices between 2015 and 2023, a law the Italian courts recently ruled constitutional. Since that sum applies to earlier years, we've normalized for it in figuring our expected 2025 revenue growth rates. You can find the comparable GAAP figures and our GAAP-to-non-GAAP reconciliation in the press release we posted. For Q4, which ended December 31, 2024, total revenues came to $321.3 million — up 12.9% adjusted and 13% in constant currency versus the fourth quarter of 2023. Sales by geography in Q4 2024 split 77.2% U.S. and 22.8% international. Our U.S. region posted 21.7% growth, powered by a 27.3% gain in our thrombectomy franchise. International regions fell 9.4% adjusted and 9.1% in constant currency, mainly because China revenue dropped $15.4 million, partly offset by a $7.8 million rise across all other international regions. Total revenue grew 6.7% sequentially, mostly from a $18.6 million increase in U.S. thrombectomy revenue, with international revenue roughly flat. Turning to revenue by product, our global thrombectomy business brought in $222.7 million during Q4 2024 — up 16.8% adjusted and 16.9% in constant currency from the same period a year earlier. The 27.3% U.S. gain stems mainly from strong growth in both vascular and neurothrombectomy. Our international business dropped 13.9%, chiefly because China revenue fell $15.8 million, partly offset by growth in all other international regions compared with the same period last year. Revenue from the embolization and access business reached $98.6 million in Q4 2024 — up 5% adjusted and 5.1% in constant currency, matching our expectations and driven mainly by an increase in the U.S. Gross margin for Q4 2024 came in at 67.4%, versus 65.7% for Q4 2023 — a 170 basis point gain, thanks to favorable thrombectomy product mix across every region plus strong productivity improvements. On a sequential basis, gross margin improved 80 basis points, reflecting a richer thrombectomy product mix from new product launches and favorable regional mix. Total operating expense for the quarter was $167.9 million, or 52.3% of revenue, against $149.6 million, or 52.5% of revenue, in the same quarter last year. Research and development expenses for Q4 2024 were $20 million, or 6.2% of revenue, compared with $21.9 million, or 7.7% of revenue, for Q4 2023. For the fourth quarter of 2024, SG&A came in at $147.9 million, representing 46.1% of revenue, versus $127.7 million, or 44.8% of revenue, in Q4 2023. Operating income was $48.6 million, or 15.1% of revenue, against $37.4 million, or 13.1% of revenue, during the same quarter a year ago. Adjusted EBITDA reached $63.7 million, or 19.8% of total revenue, up from $53.4 million, or 18.8%, in last year's fourth quarter. Turning to the full year 2024, total revenue came to $1.2 billion, marking a 13.4% rise on an adjusted basis and in constant currency versus full year 2023. The geographic split of our sales for the year was 75.1% U.S. and 24.9% international. During full year 2024, U.S. reported growth of 19.1%, mainly fueled by expansion in our vascular thrombectomy business, whereas our international regions declined 1% adjusted and 1.1% in constant currency, largely because of a $39.5 million reduction in China revenue, partly offset by gains across all other international regions. Our global thrombectomy business generated $818.1 million in revenue for full year 2024, up 20.8% adjusted and in constant currency. Revenue from our global embolization and access business for full year 2024 totaled $382.3 million, up 0.3% adjusted and 0.2% in constant currency. Gross margin for the year stood at 63.4%, including a one-time $33.4 million Immersive Healthcare inventory write-off, versus 64.5% of revenue for full year 2023. For 2025, after excluding that one-time item, which affected our 2024 gross margin by 280 basis points, we are targeting at least 100 basis points of gross margin expansion, bringing it above 67% for full year 2025. This reflects continued favorable thrombectomy product mix, productivity gains, and investment supporting new product launches. Operating income for the full year was $106.6 million, including the one-time $33.4 million Immersive Healthcare inventory write-off, compared with operating income of $101.3 million for 2023. As an update on the impact of winding down the Immersive Healthcare business, we achieved GAAP operating expense savings of roughly $16 million for 2024, and we remain on track to deliver annualized GAAP operating expense savings of approximately $40 million. Our Adjusted EBITDA for 2024 was $171 million, or 14.2% of total revenue, versus 16.1% last year. Looking ahead to 2025, as Jason will soon discuss, we project operating margin expanding to a range of 13%-14% of total revenue. Moving to cash flow and the balance sheet, we closed the fourth quarter with cash, cash equivalents, and marketable securities of $340.1 million and no debt, a sequential increase of $49.1 million, powered by strong operating profitability and better working capital management. We anticipate positive operating cash flow trends continuing in 2025 and beyond. And now I'd like to hand the call over to Jason to discuss our 2025 guidance.

Jason Mills

executive
#4

Thanks, Maggie, and good afternoon to all of you. In line with the guidance approach we laid out during our second quarter 2024 earnings call, we're guiding total revenue for 2025 to a range of $1.340 billion to $1.360 billion, reflecting growth of 12% to 14% over 2024 GAAP total revenue on a year-over-year basis; within our U.S. thrombectomy business, we anticipate year-over-year growth of 19% to 20%. Further down the income statement, our expectation is that both gross margin and operating margin will expand in 2025. Regarding gross margin, once we exclude the one-time expense Maggie discussed earlier, we project at least 100 basis points of expansion in 2025, bringing the full year to more than 67%. Turning to the operating margin line, we anticipate expansion to 13% to 14% of total revenue for full year 2025, measured against operating margin in 2024, which excludes the one-time expense described previously. Looking ahead, as Adam noted in his remarks, we remain on track to reach a gross margin profile above 70% by the end of 2026, in line with the timeline we communicated before, and we expect operating margin expansion to outpace gross margin expansion for the foreseeable future. That wraps up our prepared remarks. Operator, we're ready to open the call to questions.

Larry Biegelsen

analyst
#5

Good afternoon, and thank you for taking my question. Nice work finishing the year on a strong note. Adam, I have two things — one on guidance, one on Thunder. From what I can tell, adjusted revenue growth for 2024 landed at 13.5%, or maybe 13.4%. Your 2025 guide is 12% to 14%. With the one-time headwinds we saw in 2024 — the European launch delays, some of the China sales impact, and Thunderbolt — why shouldn't we be looking for faster growth in 2025? So philosophically, how are you thinking about guidance this year and about winning back some of those 2024 headwinds? I have a follow-up too.

Adam Elsesser

executive
#6

Yes, Larry, I appreciate that question, and I'd say it's a fair one. We aimed to be fairly explicit when providing that guidance, noting it aligned with the approach we described during Q2 of not racing ahead of where we are. Clearly, several factors remain outside our full control. Thunderbolt, which you asked about next, is one of those, so until we learn more about it, we won't include it in the guidance. You're right to point out that we faced a number of challenges during the past year and managed to work past them, and that the majority of those aren't present now. Our intention is to set guidance sensibly, so we avoid landing in the same difficult situation we encountered previously.

Larry Biegelsen

analyst
#7

That's useful. And Adam, my follow-up concerns Thunder. It sounds like the follow-up has wrapped up. What should our expectations be regarding the timeline for data readout, filing, and clearance? And as a second question, at ISC a couple of weeks ago, we saw three negative trials involving medium and distal vessels. What does that mean for Penumbra? Thank you.

Adam Elsesser

executive
#8

Yeah, regarding Thunderbolt, we will certainly give you an update when appropriate and when there's additional information to share, both on the timing of clearance and on presentation of the data and so forth; it's simply too early for that and to begin speculating publicly, obviously. I think you understand that. When it comes to the distal trials, there was a bit of a feeling of déjà vu. As you're aware, those studies mainly relied on stent retrievers, and employing stent retrievers in distal vessels in particular as a main approach rather than as a supplement is, in most cases, not something that ought to be the primary strategy. And that outcome didn't catch us off guard. We've consistently discussed the opportunity as really encompassing just large vessel occlusions, meaning the M1, rather than the more distal ones. I know many people have achieved excellent results with aspiration, especially with our smaller catheters, RED 43 and RED 62, in certain distal vessels, and I think, as with everything, especially given what we've observed across 20 years in stroke, the story isn't finished yet, and I believe we'll continue to see a shift toward aspiration as the main mechanism, partly because it simply makes sense, and partly due to studies such as that one.

Larry Biegelsen

analyst
#9

All right. Thanks so much.

Adam Elsesser

executive
#10

Thank you.

Robbie Marcus

analyst
#11

Oh, excellent. Let me add my congrats for a solid quarter. I'd like to ask about the remaining portion of the business, embolization plus access — what are you observing in that area? If my calculations are correct, that suggests either no change or a decline of 5% in sales for 2025. So I just hoped to understand what you're seeing in that space, domestic against international, and what factors are shaping the 2025 guidance. Many thanks.

Adam Elsesser

executive
#12

Yes. So if you examine our embolization and access operations, we possess an extremely robust business across both of those segments. On the vascular side with coils, and on the neuro side with access, we truly are the leader in the market. That represents a hugely significant portion of what we do. We take great pride in it. I believe you caught in my prepared remarks that innovation in those spaces is not finished for us. I suspect that's going to be something we monitor and concentrate on as the year moves forward. Additionally, now that we've grown larger and our focus on the CAVT has broadened so tremendously, we must ensure we retain the capacity to focus; and I choose that word with real intention. So I believe there are numerous possibilities, especially within the U.S., over the near term, to keep seeing growth there. Naturally, during the prior year, we did a certain amount of pulling back. We explicitly stated that in markets where we hadn't succeeded, we would essentially enter those areas and intensify our efforts in places where we can achieve more success abroad too. Demand is substantial, and with the capability to — especially for markets outside the U.S., but domestic markets as well, when appropriate — as we grow our manufacturing facility in Costa Rica, there's a chance to establish a cost structure that better suits certain of those markets too.

Robbie Marcus

analyst
#13

Great. Thanks a lot, Adam.

Adam Elsesser

executive
#14

Thank you.

Macaulay Cobain

analyst
#15

Hello, everybody. Macaulay here, filling in for Margaret this evening. We appreciate you answering our question. I was hoping to dig deeper into the guidance topic, and we're grateful for the remarks regarding U.S. thromb specifically, but considering the 41% VT expansion in the U.S. that occurred this quarter, I'm just curious whether you could clarify what's baked into that — whether it's vascular or neuro — and no, Thunderbolt's launch isn't part of it, or simply any thoughts zeroing in on vascular especially across PE, DVT, and arterial here in the U.S.

Adam Elsesser

executive
#16

Yeah. See, that guide covers all of the businesses holistically. We don't separate it out segment by segment when providing a guide; yet clearly, based on the way we finished 2024, we have a lot of confidence in those markets where CAVT is fueling the expansion. And that's the emphasis — you clearly noticed that standout figure, the 41% within the VTE business. There's also a pretty stubborn rival of ours in that space, and even so we managed to achieve that level of growth, since the product clears the clot quicker and with greater safety. We've been saying this for some time. Not every product is equivalent. You can't simply offer one thing and expect to compete in the market. You need something that performs on par with whatever currently leads the category. And I believe it's quite evident at this point that CAVT is establishing that standard. So naturally, looking forward, we'll be cautious about getting too far ahead of ourselves. We won't do that. What additional share remains available? What additional market expansion remains? And we'll monitor all of that quarter by quarter, and we'll revise as needed. But clearly, we aim to be sensible as we begin the year with the guide we currently have.

Macaulay Cobain

analyst
#17

Got it. Then, perhaps only to follow up, I wanted to — or noticed that a few days back there was an update regarding the RED 72 510(k) status; and Adam, I couldn't help noticing that in your script you stressed the part about FDA clearance; so did the catheter undergo any changes there? Or, I suppose, looking at the larger picture, what ought we to anticipate from that catheter pipeline going forward?

Adam Elsesser

executive
#18

Yes, I believe that's a reasonable question. I'm pleased you caught that. So, as I think all of you are aware, we continually make our products better. For close to 20 years, that has been the defining feature of our success. We've never really declared that we were finished. And RED 72 came out now, what, three, four years back? I've stopped keeping track of time; and so it makes sense that we'd refresh that catheter using technology we've created while developing other catheters; so this simply makes the RED 72 significantly more trackable. Clearance came just at the end of last week. I believe we've already completed approximately half of our evaluation cases within a brief window. And we'll share additional details as things progress. But clearly, when you have a suite of catheters that contract to the clot faster and better than anything else available on the market, and then Thunderbolt is added on top of that once it gets cleared, it places us where we can assist the largest number of patients possible. And you pair that with the best-in-class sales team. And I think we'll have a fairly strong chance to create additional impact this year with our stroke business.

Macaulay Cobain

analyst
#19

That all makes sense. Appreciate you fielding the questions, and once more, congratulations on the quarter.

Adam Elsesser

executive
#20

Thanks.

Pito Chickering

analyst
#21

Hey, everyone. Good afternoon. I appreciate you taking my questions. When I look at the U.S. thrombectomy guide, 19%-20% at the end of the year, and clearly 27%. What's the right way to consider seasonality for that growth, similar to the comps in 2024? Your Q4 exit rate was such a big figure that if we take that growth and straight line it, it's nearly flat on a sequential basis, and we haven't really observed that since you launched, and you mentioned how strong December was.

Adam Elsesser

executive
#22

Yeah. I'll begin, and Jason can address the rhythm a bit more. There's always some mix of seasonality because, I mean, we've consistently seen the fourth quarter, perhaps it's holiday stress and similar factors. For instance, the stroke business rises and so forth. Having said that, we've also layered on different launches. And clearly, we haven't discussed launches and timing for 2025. But that shifts, once again, the capacity to simply straight line things and run them out. And then you also factor in what I referenced when answering the prior question, that as you gain share, whether in stroke or in VTE, that share doesn't arrive evenly. It arrives in chunks and then pauses, and then you gain more; and we've observed that for many, many, many years; with that as a sort of baseline, Jason can provide some color on that.

Jason Mills

executive
#23

Okay, Pito, I appreciate that question. The way you can tell, Q4 turned out to be our largest quarter for sequential expansion within the U.S. thrombectomy segment. And if you look at it year over year, the way you can also tell, it ranked among the quickest. From a U.S. thrombectomy standpoint, it was a remarkable quarter, and that alone means Q4 of 2025 becomes the toughest comparison, which tells you that while you're building your model inside that 19%-20% band, you could likely begin the year either at the midpoint or above it. Then Q4 can capture the reality that Thunderbolt isn't included in our guidance and can land around the midpoint or below; so in terms of the growth guidance we provided, the year leans more toward being front-end loaded.

Pito Chickering

analyst
#24

All right. And if we stay on that 27% expansion for this quarter, can you give any detail on how much came from price and how much from volume during the period? And when we look at 2025, should we think about U.S. thrombectomy price versus volume inside the guidance range?

Adam Elsesser

executive
#25

Yes. By this point, we're multiple years into this. It's volume. It's volume. Price isn't a factor anymore. This was simply.

Pito Chickering

analyst
#26

Great, thank you very much.

Adam Elsesser

executive
#27

That's the reason I deliberately emphasized that we closed out the year with the highest case volume in our history, across both VTE and arterial.

Bill Plovanic

analyst
#28

Great, thanks, and good evening. I appreciate you taking my questions. Starting with Thunderbolt, I just want to get a few things straight. First, has the FDA received a submission from you? Second, have you talked with the agency at this point? Third, is the agency requesting anything further, such as extra clinical trials? I'm simply attempting to determine the stage we've reached, and then I have another question to ask.

Adam Elsesser

executive
#29

That's a solid set of questions. Let me simplify it: no submission has been made by us yet. As a result, none of those discussions have taken place.

Bill Plovanic

analyst
#30

Alright.

Adam Elsesser

executive
#31

To reiterate, a bit under 1 month back, we wrapped up the study and collected every piece of data; and clearly, some time is needed to arrange and adjudicate that. There is a procedure involved there. Therefore, if it were possible for it to be available sooner now, that would indicate you were clearly bypassing a stage in the process, something we clearly never do.

Bill Plovanic

analyst
#32

No, thank you. Turning to R&D — $20 million is genuinely a low point, the likes of which we haven't seen in nearly two years. Is that the new normal for R&D spending in nominal terms? Should we treat it as a baseline going forward and expect most of the operating margin leverage to come off it? Thanks for taking my questions.

Adam Elsesser

executive
#33

Yeah. I mean, I think it was pretty clear — I believe I used this phrase — that we intend to invest aggressively in innovation. So R&D spend shifts from quarter to quarter based on what's on the docket, whether we have certain types of testing, certain this and that. What you'll see is that it shifts depending on the workload we've got in front of us, rather than following some sort of structured or manufactured spending plan, so there's nothing to be inferred from this quarter specifically. Looking at our overall spending has given a fairly reliable picture, and I believe that's something everyone would agree with. With nine product launches in the past year, our R&D group operates quite efficiently, and the team keeps delivering remarkable innovation while keeping expenditure at a reasonable level. That said, we have no intention of pulling back. Plenty of innovation lies ahead. My sense is that we have many more years of ongoing innovation in front of us. We're not going to detail all of that, though our pace of innovation isn't going to slow down anytime soon.

Jason Mills

executive
#34

Also, Bill, one more point from me on that: Maggie brought up during her comments the amount saved up to now from getting out of Immersive Healthcare. A strong share of those costs sits within R&D. We don’t separate out what we put into the interventional side compared with what we used to spend on R&D and Immersive Healthcare. It’s enough to say that, just as Adam noted in his prepared remarks, we keep investing heavily in innovation, clearly on the interventional side.

Richard Newitter

analyst
#35

Hello, and thank you for allowing me to ask. Congratulations on the results and the strong close to the year. Adam, perhaps you brought up a number of new product introductions, and the timing swings of those can shape how any given quarter turns out. Could you refresh our memory? You referenced 9 launches during 2024. What number do you have in mind for 2025? And any steer on where those might add value and address an unmet need that isn't covered today?

Adam Elsesser

executive
#36

Sure. What I won't do is give a specific figure, exactly as we refrained from doing a year ago. We didn't open the year declaring there would be 9 launches, and we don't even make announcements about them. The 3 tied to CAVT, I believe everybody is aware of, yet as for the remaining 6, I suspect the majority of people haven't paid attention. Those have delivered quite a favorable effect on our business overall too. So we won't walk through all of them. The single one that clearly is a candidate on that list — we've already discussed it a few times, Dan — is Thunderbolt, naturally. As for the others, we'll hold off until those products receive clearance, and at that point we'll gladly discuss them.

Richard Newitter

analyst
#37

All right. And I just want to make sure we're on the same page — hitting the range you've guided to doesn't require Thunderbolt. Said differently, that isn't stated outright.

Adam Elsesser

executive
#38

Correct. Thunderbolt revenue isn't included in our guidance right now, and the reason is simple: it's not that we view it as anything less than a terrific product, and it's not that we lack tremendous confidence in the position we've reached with it — it's that the process isn't entirely within our hands. Given that, we'll take a cautious approach, which means we won't need to revise our guide over a factor we can't control.

Richard Newitter

analyst
#39

All right, thanks, and I’ll sneak in a final one about Thunderbolt. Should we look for a conference presentation for this, or might a press release land sometime in the middle of the year? How are you approaching it?

Adam Elsesser

executive
#40

Yeah, it really comes down to when it happens. Because the clearance is in the U.S., there are essentially 2 big American meetings, with 1 falling in July and the other in November. So if approval comes at a point that isn’t near either of those, we clearly wouldn’t hold off on sharing the data so we could start selling the product, and that clearly means people might learn about it ahead of the official data presentation.

Richard Newitter

analyst
#41

Thank you very much.

Adam Elsesser

executive
#42

Thank you.

Samantha Graham

analyst
#43

This is Samantha, filling in for Matt. Thanks for letting us ask. A number of studies are underway involving aspiration thrombectomy devices, more or less across both the peripheral side and the neuro side. In the near term, how do you view enrollment in those studies affecting sales growth, or possibly helping expand the market over a longer horizon?

Adam Elsesser

executive
#44

Yeah. There are several of them. I'd say you framed it correctly. Clearly it isn't really affecting our sales. That was fairly evident this quarter, I believe. When you actually talk with the doctors who use many of those products, it kind of gives you the true picture. And I think we'll stay focused. We don't believe that alters our strategy, alters our momentum, or anything along those lines.

Samantha Graham

analyst
#45

Thanks.

Michael Sarcone

analyst
#46

Hi there, and I appreciate you taking my question. To kick things off, 2024 saw China act as quite a significant drag, roughly 300 or 350 basis points. Could you share which assumptions regarding China you've incorporated into 2025? Guidance? Has it more or less leveled off at this point? What's your perspective on that?

Adam Elsesser

executive
#47

Yes. No questions exist. China, as everybody discusses the market and its implications for medical device companies headquartered in the U.S., the arrangement we described contained several distinct components. However, the component that counted during this stage would have been essentially for product made or based in the U.S. And that market truly isn't accessible for some time. There's a slight drag early in the year. Yet beyond that, I believe we essentially have that behind us. And once more, I think when you consider what we've stated and the opportunity before us, certain international markets will prove highly significant. And we've discussed those markets. What's important regarding scale and growth shifts annually; and I think we've, just to remind everybody, we've been selling abroad for over 18 years, and we possess fairly solid insight into international markets and what's workable and what isn't. That's also the reason you'll witness ongoing disproportionate growth within the U.S. given the volume of patients. Once more, 800,000 patients within the U.S. by itself, over 90% of the market open to us provided we perform the work we described, which is ongoing share gains plus ongoing market access efforts so we can expand the market via hospitals completing the work required to guarantee they treat every patient they're able to treat. Combining all of that, I think we're positioned incredibly strongly across many years; and afterward the international markets rise and fall depending on their respective economies and everything else as we move ahead.

Jason Mills

executive
#48

Correct, Michael. To build on what was said, your point stands. In fact, the pressures originating solely from China during 2024 turned out a bit larger than the figure you gave in your response. And like Adam noted, we expect to encounter the final portion of those pressures during 2025, meaning that by next year they will be minimal or essentially gone; 2025 won't carry quite the same burden as 2024 did, though some pressure remains, particularly across the first six months. So when you examine our guidance and break down growth in the U.S. against growth internationally, once China is taken out, growth actually speeds up across all businesses; and the drag caused by China, once again, will show up during the first half; therefore, regarding the 12%-14% guidance, that impact will be visible in the first half when it comes to year-over-year growth, and China is the reason.

Michael Sarcone

analyst
#49

Understood, that's useful. Thank you, Adam and Jason, and perhaps for my follow-up question, earlier in this year we have observed a certain amount of M&A activity within the space. I just wanted to hear your perspective regarding whether you are preparing for any shifts in competitive dynamics, or whether any possible disruption might be on its way that you could take advantage of. Thanks.

Adam Elsesser

executive
#50

At this point, I won't really discuss specific tactics and similar competitive matters. What I can say is that, broadly speaking, we definitely welcome new owners entering the field, yet that truly has no impact on our strategy, or so we believe, on our current momentum in the field.

Michael Sarcone

analyst
#51

Great. Thank you, Adam.

Adam Elsesser

executive
#52

Thank you.

Ryan Zimmerman

analyst
#53

Hey, thanks for taking my question. I'd like to discuss gross margins for a moment, since when you run the numbers, reaching that 70% exit rate in 2026 does suggest a fairly sizable jump in gross margins that year. Help me understand. I mean, is that just a — go ahead. Or Maggie.

Maggie Yuen

executive
#54

Yeah, yeah. Thanks for the question. Well, essentially, nothing fundamental has shifted in the drivers beneath what you've observed this year. I mean, better product mix, along with regional mix, accounted for most of the margin expansion drivers. Looking back at 2024, I mean, you've seen pretty good momentum in our sequential quarterly growth. For 2025, we're anticipating that same pattern will carry forward. And should that pace keep up, my sense is you'd see us hit that 70% goal right on the nose at some point during 2026.

Ryan Zimmerman

analyst
#55

All right, but I want to make sure we're clear on this, Maggie — that's purely driven by the mix of products, correct? It isn't tied to any pricing approaches or other things you might be considering as a way to squeeze out those additional margin gains in 2026.

Maggie Yuen

executive
#56

Correct, nothing like that. The main driver is product mix. And naturally, what I'd say is our operations group has kept a sharp focus on making the most of our overhead spending and growing our capacity. So every one of those factors works together.

Adam Elsesser

executive
#57

The thing pushing it is a combination of what we're selling and how well we're making it. Price is absolutely not the cause.

Ryan Zimmerman

analyst
#58

All right. That's very clear. Now for my follow-up, Adam, I believe this one is for you — it concerns the expansion of the sales force and the number of extra people you've brought on to build up your thrombectomy business. What I'd like to get a handle on is simply where things stand in that effort, and how you view that effort kind of hitting its stride and what it contributes, whether at present or in early 2025. And in the same vein, the same thing applies to market access, which is arguably undervalued in terms of how you're going after the market through your market access initiatives. But when do you anticipate the effects of those two forces to be felt as a result of your work? Thank you.

Adam Elsesser

executive
#59

If you were competing against us in VTE, you definitely felt it during Q4. That seems quite evident. I believe that effort is underway. It's never been linear, I've always maintained that, and nothing in this space is. Let me state plainly that it is not linear. Even so, we've done a superb job bringing aboard a remarkable team. At this moment, I sincerely, sincerely mean this. The finest commercial team ever put together in MedTech is ours. Many folks claim that about their own teams, I realize that, and I value it, and I'm pleased they do; it genuinely is the case. Our team is exceptional; and once you factor in the data we have now and that we're discussing directly with hospitals and showing them what they might do to assist more and more patients, you're sitting in a very strong position. Once more, this isn't a linear process. It never has been, yet I believe that effort has begun. Much of that stems from the fact that we now possess technology with CAVT that justifies doing so; it is plainly superior. The clot can be removed more quickly and more safely. We've demonstrated that repeatedly. We now have data, a substantial volume of data, showing the very same thing. And I think that is simply unmistakable. So I believe that will keep going. And once again, it will be a multi, multi-year undertaking since we've only reached 10% penetration in this market, and we'll keep at it until we get them all and assist all these patients. If you'll permit me a brief anecdote, our national sales meeting took place several weeks ago, and a patient came to talk about and share with the whole vascular team what had occurred. She suffered a massive PE. Unless I'm wrong, based on what she related, she had coded. She was brought back and ended up making a great recovery. And once she finished telling her story, she asked the whole commercial team that had gathered to do a single thing. And she said, "There's one thing I'd ask of every person in this room, and that's don't stop until everyone that can benefit from this technology gets this technology." We never asked her to say that. That wasn't something we prompted her to say. She spoke sincerely, as a person who had access to the finest technology out there. And that is going to drive us. It definitely did in that room. And that is what we will keep doing for many, many years.

Shagun Singh

analyst
#60

Great. Thanks a lot. I've just got one quick question. Regarding the U.S. venous thrombectomy business, you saw 41% growth year over year. How durable should we consider that to be? And since that rate has accelerated on a sequential basis over the last few quarters, I'm curious whether something else is at play. Is it purely the expansion of your commercial team? Are you observing broader acceptance because of the benefits you mentioned, a greater capacity to get in the door? Anything additional beyond what you've already told us that you could possibly share. Thank you.

Adam Elsesser

executive
#61

Yeah. Once more, I'd like to emphasize that no growth rates exist when you have market growth plus share shift occurring in a linear way. So it simply cannot be viewed like that, and it isn't. Having said that, clearly both things are taking place, and that isn't really a direct effect of having more people, so we can sell more. It's the product. The product is that effective; it removes the blood clot more quickly than any other product available on the market. And so, when people learn of it, when people are willing to try it and transition from analog technology to digital technology, they must be trained. They must go through the process. But I believe that will keep going for quite a while. You add on top the chance to treat an increasing number of people. As an increasing number of hospitals learn about that information and what they can do to accomplish that, I believe you're going to see continued strong growth, not linearly quarter by quarter, but across the next number of years, you're going to see especially strong growth persist.

Shagun Singh

analyst
#62

Thanks.

Mike Kratky

analyst
#63

Hey, everybody. Appreciate you letting us ask. Clearly, there's been a strong pickup in U.S. thrombectomy expansion, with U.S. VTE up 41%. Sorry to hit you with yet another guidance question, but even without getting into specifics, could you help us understand where each of your verticals — VTE, arterial, stroke, and coronary — is likely to fall against that 19%-20% total U.S. growth?

Adam Elsesser

executive
#64

Yeah. At this point, I'd say sharing that level of detail is premature. Clearly, each of those has its own drivers. Flash 2.0 keeps bringing in many more customers, along with the market access efforts. We've got arterial, which also has new products. And then naturally, whatever ultimately plays out with Thunderbolt, which technically isn't part of our guide, so we can't put it in, but clearly it will matter; that's before even mentioning the new RED 72 catheter, which, if it keeps performing the way the first three days of cases suggest, will be a meaningful benefit too; so I'd say we have plenty of drivers. As for the precise figures inside that, let's see how things go, and we'll share more updates once we have additional information.

Mike Kratky

analyst
#65

Got it. And perhaps only as a single additional question, could you share your thoughts regarding a few of the initial uptake patterns for Lightning Flash and Lightning Bolt 7 across Europe after the launches that happened not long ago?

Adam Elsesser

executive
#66

Yes. Once more, the constraint is that certain nations have not yet reached a point of being completely reimbursable; therefore it isn't present across all nations on a large scale, yet in the places where it is, the very same advantage we observe in the U.S. is showing up. Once again, the clot gets removed more quickly and with greater safety. And clearly, I have not yet encountered a physician who would claim that isn't a desirable objective.

Mike Kratky

analyst
#67

Understood. Thanks very much.

Adam Elsesser

executive
#68

Thank you.

Cecilia Furlong

executive
#69

Thanks, operator. From everyone on the management team, we appreciate you all once more for being with us today and for the interest you've shown in Penumbra; we're glad to bring you up to date on our call for the first quarter.

Operator

operator
#70

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.